The outcomes of patients with diabetes mellitus in The Philippine CORONA Study

Adrian I. Espiritu1,2,5,44, Harold Henrison C. Chiu3,44, Marie Charmaine C. Sy2, Veeda Michelle M. Anlacan2, The Philippine CORONA Study Group* & Roland Dominic G. Jamora2,4,5

Patients diagnosed with diabetes mellitus (DM) who are infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) belong to the most vulnerable patient subgroups. Emerging data has shown increased risks of severe infections, increased in ICU admissions, longer durations of admission, and increased mortality among coronavirus disease 2019 (COVID-19) patients with diabetes. We performed a subgroup analysis comparing the outcomes of patients diagnosed with DM (n = 2191) versus patients without DM (n = 8690) on our data from our study based on a nationwide, comparative, retrospective, cohort study among adult, hospitalized COVID-19 patients involving 37 hospital sites from around the Philippines. We determined distribution differences between two independent samples using Mann–Whitney U and t tests. Data on the time to onset of mortality, respiratory failure, intensive care unit (ICU) admission were used to build Kaplan–Meier curves and to compute for hazard ratios (HR). The odds ratios (OR) for longer ventilator dependence, longer ICU stay, and longer hospital stays were computed via multivariate logistic regression. Adjusted hazard ratios (aHR) and ORs (aOR) with 95% CI were calculated. The median age of the DM cohort was 61, with a female to male ratio of 1:1.25 and more than 50% of the DM population were above 60 years old. The aOR for mortality was significantly higher among those in the DM group by 1.46 (95% CI 1.28–1.68; p < 0.001) as compared to the non-DM group. Similarly, the aOR for respiratory failure was also significantly higher among those in the DM group by 1.67 (95% CI 1.46–1.90). The aOR for developing severe COVID-19 at nadir was significantly higher among those in the DM group by 1.85 (95% CI 1.65–2.07; p < 0.001). The aOR for ICU admission was significantly higher among those in the DM group by 1.80 (95% CI 1.59–2.05) than those in the non-DM group. DM patients had significantly longer duration of ventilator dependence (aOR 1.33, 95% CI 1.08–1.64; p = 0.008) and longer hospital admission (aOR 1.13, 95% CI 1.01–1.26; p = 0.027). The presence of DM among COVID-19 patients significantly increased the risk of mortality, respiratory failure, duration of ventilator dependence, severe/critical COVID-19, ICU admission, and length of hospital stay.

The coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and has affected over 150 million individuals worldwide as of July 19, 20211. During this period in the Philippines, our data showed a total of 1.5 million confirmed total cases; nearly 50 thousand are active cases and over 27 thousand deaths from this infection2.

Patients diagnosed with diabetes mellitus (DM) in COVID-19 are among the most vulnerable. In a meta-analysis, DM was shown to be second to hypertension as the most prevalent comorbidity among patients hospitalized...
with COVID-19, with prevalence ranging from 8.0 to 9.7%\(^1\). Studies have shown that regardless of the type of DM, these patients have 50% higher risks of acquiring lower respiratory tract infections\(^3\). Among patients with DM infected with COVID-19, several mechanisms have been postulated that can contribute to increased susceptibility: (a) impaired neutrophil recruitment, (b) impaired macrophage activity, (c) impaired interl公务员  

gamma production and release from natural killer cells, (d) impairment of antigen presentation resulting in a dysregulated immune response, cytokine storm and systemic inflammation\(^6\), and (e) increased angiotensin converting enzyme-2 (ACE-2) expression, a surface receptor expressed by epithelial cells of the lung, intestine, kidney and blood vessels causing vasodilation, and hypotension\(^7\).

Infection with SARS-CoV2 virus triggers a higher degree of stress resulting in greater release of counter-regulatory hormones and higher levels of insulin resistance, all of which leads to hyperglycemia\(^8\). Various studies have demonstrated overall poorer outcomes among patients with DM infected with COVID-19\(^9\)-\(^16\), these include increased mortality, respiratory failure, severity of COVID-19, increased utilization of intensive care, longer intensive care unit (ICU) stay, and prolonged hospital stay\(^16\)-\(^18\). Thus, early identification of patients with DM will lead to more effective management of hyperglycemia towards improving outcomes\(^16\)-\(^22\).

As COVID-19 is still presently a global pandemic, more research is needed to provide a better understanding of the effects of underlying comorbidities especially DM on COVID-19 in the setting of a low to middle income country such as the Philippines where access to healthcare services remains to be one of the major barriers in DM care. Hence, our main objective was to determine and compare the outcomes of COVID-19 patients with DM versus those without DM history in terms of COVID-19 severity, mortality, respiratory failure, COVID-19 severity, ICU admission, length of ICU stay, and length of hospital stay as these will greatly impact clinical management and patient outcomes.

**Methods**

**Study design.** We performed an analysis of patients diagnosed with DM based on the data from a nationwide, multicenter, comparative, retrospective, cohort study involving patients with COVID-19 who were admitted to our hospitals/study sites from February 2020 until December 2020\(^23\),\(^24\). All methods were carried out in accordance with relevant guidelines. The study’s protocol was registered in ClinicalTrials.gov (NCT04386083). The study was approved and endorsed by the Single Joint Research Ethics Board of the Department of Health, Philippines (SJREB-2020–24) and the independent hospital institutional review boards (see Appendix 1). All the institutional review boards mentioned waived the need for informed consent since this study used a method of naturalistic observation. The data was obtained only though review of medical records retrospectively. Moreover, the data collection forms used did not contain any information that could determine or identify the patients.

**Setting.** The Philippine CORONA (COVID-19 Outcomes: a Retrospective study Of Neurological manifestations and Associated symptoms) study encompassed a total of 37 major hospitals/study sites from various regions in the Philippines (see Appendix 2)\(^23\),\(^24\).

**Data collection, patient selection, sampling and cohort description.** We conducted a nationwide, multicenter study involving 37 institutions in the Philippines. The cases were identified using the designated COVID-19 censuses of all the participating centers. A total enumeration of patients admitted with confirmed COVID-19 disease with a discharge disposition was done in this study. The following pertinent data were obtained through review of medical records and encoded using an electronic data collection form using Epi Info Software (V.7.2.2.16): (a) demographic data; (b) other clinical profile data/comorbidities; (c) neurological history; (d) date of illness onset; (e) respiratory and constitutional symptoms associated with COVID-19; (f) COVID-19 disease severity at nadir; (g) data if neurological manifestation/s were present at onset prior to respiratory symptoms and the specific neurological manifestation/s present at onset; (h) neurological symptoms; (i) date of neurological symptom onset; (j) new-onset neurological disorders or complications; (k) date of new neurological disorder or complication onset; (l) imaging done; (m) cerebrospinal fluid analysis; (n) electrophysiological studies; (o) treatment given; (p) antibiotics given; (q) neurological interventions given; (r) date of mortality and cause/s of mortality; (s) date of respiratory failure onset, date of mechanical ventilator cessation and cause/s of respiratory failure; (t) date of first day of ICU admission, date of discharge from ICU and indication/s for ICU admission; (u) other neurological outcomes at discharge; (v) date of hospital discharge; and (w) final disposition.

We included all patients analyzed in The Philippine CORONA Study\(^23\),\(^24\). Patients with DM were identified through history of having diabetes mellitus diagnosed using any of the following criteria: fasting blood glucose of ≥ 126 mg/dL, hemoglobin A1c (HbA1c) of ≥ 6.5% and random blood sugar of ≥ 200 mg/dL in the presence of symptoms of hyperglycemia. Adult COVID-19 patients who had DM were grouped under the exposed cohort while those without DM (non-DM) were classified under the unexposed cohort.

**Outcome variables.** We obtained the following relevant patient outcomes: (a) mortality; (b) COVID-19 severity at nadir defined as the worst covid classification of severity the patient experienced during the admission, disease severity was defined as mild: defined as presence of mild pneumonia or absence of pneumonia; severe disease: defined as the presence of dyspnea, respiratory rate > 30 breaths/minute, hypoxia (SpO2 < 93%) or >50% lung involvement on imaging within 24–48 h; and critical disease: defined as the presence of respiratory failure, shock or multiorgan dysfunction; (c) respiratory failure (patients with clinical symptoms/signs of respiratory insufficiency defined as increased work of breathing/tachypnea [respiratory rate > 22], a necessity to administer supplemental oxygen, or abnormal blood gases [partial pressure of oxygen < 60/ hypoxemia or partial pressure of carbon dioxide > 45/ hypercapnia]); (d) duration of ventilator dependence (DVD) (days from the...
A considerable proportion of patients received systemic glucocorticoids (n = 1105, 50.4%), remdesivir (n = 769, 35.1%), and tocilizumab (n = 464, 21.18%). Other pertinent clinical features and comparison of characteristics are presented in Table 1.

Statistical analysis. Baseline characteristics and clinical outcomes of the participants were summarized by descriptive statistics. Numerical variables were described as mean and standard deviation (SD), if the data was normally distributed as assessed by Shapiro–Wilks test for normality, and as median and interquartile range (IQR), if otherwise. Categorical variables were described as counts and proportions. These different baseline characteristics and clinical outcomes were compared between diabetics and non-diabetics. Significant difference in the mean/median/mean-rank of the different numerical variables was determined by Student’s t test for the variables with normally distributed data, while Mann–Whitney U test was done for non-normally distributed variables. Heterogeneity of the proportions of the different categorical variables was determined by chi-square test or Fisher exact test.

The associations between history of DM and the different individual dichotomous outcome variables of interest were determined by multivariable binary logistic regression. Survival analysis was also done for time-to-event data of mortality, respiratory failure, and admission to ICU. The time-to-event were right-censored on time-to-discharge as the exit from the time-at-risk among those who have not experienced the event, i.e., mortality or respiratory failure, or admission to ICU, during the hospital stay. The associations between history of DM and the different time-to-event outcome variables of interest were determined by multivariable Cox proportional hazards regression. The logistic regression and Cox proportional hazards models were adjusted for the following pre-determined confounders: age group, sex, smoking status, hypertension, chronic cardiac disease, chronic respiratory disease, chronic kidney disease, chronic neurologic disease, chronic liver disease, and HIV/AIDS. A cutoff of p-value < 0.05 identifies history of DM as significant predictor of the different outcomes of interest.

Kaplan–Meier curves were constructed to visualize the survival curves of DM versus non-DM, and log-rank test was used to identify significant differences in the survival curves across between diabetics and non-diabetics; log-rank test with p-value < 0.05 was considered significant. All statistical analyses were conducted using Stata®, Version 7.2.2.16 (College Station, TX: StataCorp LP).

Results

Inclusion of patients. We identified hospitalized patients diagnosed with DM and COVID-19 verified via reverse transcription polymerase chain reaction from the 37 participating study sites. A total of 10,881 were included in the qualitative and quantitative analyses. Two thousand one hundred and ninety-one patients were identified with the primary exposure (DM group) while the remaining 8690 did not have diabetes (non-DM).

Demographic and clinical characteristics of included COVID-19 patients with diabetes mellitus. The median age of the DM cohort was 61 with a female to male ratio of 1:1.25. More than 50% of the diabetic population were more than 60 years old (n = 1218, 55.6%). Hypertension (HPN) (n = 1643, 75.0%), HIV/AIDS (n = 460, 20.1%), and chronic respiratory disease (n = 297, 13.5%) were the most common comorbidities. A considerable proportion of patients received systemic glucocorticoids (n = 1105, 50.4%), remdesivir (n = 769, 35.1%), and tocilizumab (n = 464, 21.18%). Other pertinent clinical features and comparison of characteristics are presented in Table 1.

Effects of diabetes mellitus on outcomes of included COVID-19 patients and survival analysis. The comparison of clinical outcomes between COVID-19 patients with DM versus those without DM are shown in Table 2. The adjusted odds ratio for mortality, respiratory failure, COVID-19 severity, ICU admission, length of ICU admission, and length of hospital stay are shown in Table 3. The adjusted odds ratio for the time-to-event analysis for mortality, respiratory failure, and ICU admission are shown in Table 4. Figures 1, 2, and 3 shows the Kaplan–Meier cumulative hazard functions for DM and non-DM groups in terms of mortality, respiratory failure, and ICU admission, respectively.

Mortality. A total of 1702 (15.6%) died in the full cohort. Patients with DM had a significantly higher in-hospital mortality rate (n = 579, 26.4%) compared to those without DM (n = 1123, 12.9%; p < 0.001). The adjusted OR for mortality was significantly higher among those in the DM group by 1.46 (95% CI 1.28–1.68; p < 0.001) than those in the non-DM group (see Table 3). Furthermore, time-to-event analysis showed an adjusted HR remaining significantly higher by 1.19 (95% CI 1.06–1.33; p = 0.002) in the DM group compared to those in the non-DM group (see Table 4, Fig. 1).

Respiratory failure. A total of 1608 (14.8%) patients had respiratory failure. A higher proportion of patients with DM had respiratory failure (n = 656, 29.9%) as compared to the non-DM group (n = 952, 10.9%, p < 0.001). The adjusted OR for respiratory failure was significantly higher among the DM group by 1.67 (95% CI 1.46–1.90) than in the non-DM group (Table 3). Furthermore, time-to-event analysis showed an adjusted HR remaining significantly increased by 1.51 (95% CI 1.35–1.69; p < 0.001) in the DM group than those in the non-DM group.

Duration of ventilator dependence (DVD). Among patients needing mechanical ventilation, the overall median DVD was 13 days (IQR 8–20). There was a significant difference in the median DVD between patients start of assisted ventilation to cessation); (e) ICU admission (COVID-19 patients admitted to an ICU or ICU-comparable setting; (f) length of ICU stay (LICUS) (days admitted in the ICU); and (g) length of hospital stay (LHS) (days from admission to discharge).

Sample size. The total sample of patients analyzed was 10,881: 2191 have DM versus 8690 without DM. 
with DM (median of 14 days) and non-DM groups (median of 12 days; \(p = 0.002\)). The adjusted OR for longer \(\text{DV}(\text{D})\) (i.e., more than 14 days) was statistically significant at 1.33 (95% CI 1.08–1.64; \(p = 0.008\)).

Severe/critical COVID-19 at Nadir. A significantly higher proportion of patients with DM had severe/critical COVID-19 (n = 1245, 57.4%) as compared to those without DM (n = 2816, 32.8%; \(p < 0.001\)). The adjusted OR for severe COVID-19 was significantly higher in the DM group by 1.85 (95% CI 1.65–2.07; \(p < 0.001\)) than those in the non-DM group (Table 3).

ICU admission. A total of 1740 patients (16.0%) from our full cohort were admitted to the ICU. A significantly higher proportion of patients with DM were admitted into the ICU (n = 739, 33.7%) as compared to those without (n = 1001, 11.5%; \(p < 0.001\)). The adjusted OR for ICU admission was significantly higher in the DM group by 1.80 (95% CI 1.59–2.05) than in the non-DM group (see Table 3). Furthermore, the time-to-event analysis showed an adjusted HR remaining significantly increased by 1.57 (95% CI 1.41–1.74; \(p < 0.001\)) in the DM group as compared to the non-DM group.

Length of ICU stay (LICUS). Among those patients admitted to the ICU, the overall median LICUS was 15 days (IQR 9.5–21). There was no significant difference in median LICUS between patients in the DM

| Table 1. Baseline characteristics stratified by history of diabetes. aIncludes heart failure, coronary artery disease, prior history of myocardial infarction, and other cardiac conditions. bIncludes bronchial asthma, chronic obstructive pulmonary disease (COPD), restrictive lung disease, and other pulmonary conditions. cIncludes remdesivir, lopinavir, ritonavir. dIncludes chloroquine, hydroxychloroquine, convalescent plasma, and other therapies. | Diabetic (n = 2191) | Non-diabetic (n = 8690) | \(p\)-value |
|---|---|---|---|
| **Socio-demographic data** | | | |
| Age, median (IQR) | 61 (18) | 48 (29) | < 0.001 |
| Age group | | | |
| \(18 – 59\) years, n (%) | 973 (44.41%) | 6074 (69.90%) | < 0.001 |
| \(\geq 60\) years, n (%) | 1218 (55.59%) | 2616 (30.10%) | |
| Female, n (%) | 975 (44.50%) | 4124 (47.47%) | 0.013 |
| Ever-smoker (past/current), n (%) | 321 (14.65%) | 705 (8.11%) | < 0.001 |
| **Clinical characteristics** | | | |
| **Non-neurologic comorbidities** | | | |
| Hypertension, n (%) | 1643 (74.99%) | 2004 (23.06%) | < 0.001 |
| Chronic cardiac disease\(a\), n (%) | 185 (8.44%) | 431 (4.96%) | < 0.001 |
| Chronic respiratory disease\(b\), n (%) | 297 (13.56%) | 314 (3.61%) | < 0.001 |
| Chronic kidney disease, n (%) | 22 (1.00%) | 38 (0.44%) | 0.001 |
| Chronic liver disease, n (%) | 64 (2.92%) | 180 (2.07%) | 0.016 |
| Malignancy, n (%) | 3 (0.14%) | 34 (0.39%) | 0.068 |
| HIV/AIDS, n (%) | 460 (20.99%) | 1279 (14.72%) | < 0.001 |
| **Number of non-neurologic comorbidities, median (IQR)** | 2 (1) | 0 (1) | < 0.001 |
| **Non-neurologic presenting symptom, n (%)** | 2029 (92.61%) | 5037 (57.96%) | < 0.001 |
| Fever, n (%) | 1301 (59.38%) | 2626 (30.22%) | < 0.001 |
| Cough, n (%) | 1444 (65.91%) | 2967 (34.14%) | < 0.001 |
| Dyspnea, n (%) | 948 (43.27%) | 1755 (20.20%) | < 0.001 |
| Rhinorrhea, n (%) | 123 (5.61%) | 484 (5.57%) | 0.936 |
| Sputum production, n (%) | 214 (9.77%) | 423 (4.87%) | < 0.001 |
| Sore throat, n (%) | 155 (7.07%) | 596 (6.86%) | 0.722 |
| Diarrhea, n (%) | 150 (6.85%) | 447 (5.14%) | 0.002 |
| Fatigue, n (%) | 239 (10.91%) | 474 (5.45%) | < 0.001 |
| Others, n (%) | 375 (17.12%) | 1299 (14.95%) | 0.012 |
| **Treatment/received** | | | |
| Glucocorticoids, n (%) | 1105 (50.43%) | 1739 (20.01%) | < 0.001 |
| Tocilizumab, n (%) | 464 (21.18%) | 565 (6.50%) | < 0.001 |
| Antiviralc, n (%) | 769 (35.10%) | 1133 (13.04%) | < 0.001 |
| Antibacterial, n (%) | 2042 (93.20%) | 6972 (80.23%) | < 0.001 |
| Others\(d\), n (%) | 987 (45.05%) | 2918 (33.58%) | < 0.001 |
### Table 2. Comparison of clinical outcomes in COVID-19 patients with diabetes mellitus vs. without diabetes mellitus. *Derived from overall length of stay for patients who were never admitted to ICU; excludes ICU length of stay for those who were admitted in the ICU. **Patients who had a neurologic presentation or concomitant acute neurologic diagnosis on admission (n = 2291).

| Outcomes                                      | Diabetic (n = 2191) | Non-diabetic (n = 8690) | p-value |
|-----------------------------------------------|---------------------|-------------------------|---------|
| Final outcome                                 |                     |                         |         |
| In-hospital mortality, n (%)                  | 579 (26.43%)        | 1123 (12.92%)           | < 0.001 |
| Discharged, n (%)                             | 1612 (73.57%)       | 7567 (87.08%)           | < 0.001 |
| Time to in-hospital mortality in days, median (IQR) | 16 (14)             | 14 (13)                 | < 0.001 |
| Respiratory failure, n (%)                    | 656 (29.94%)        | 952 (10.96%)            | < 0.001 |
| Duration of IMV in days, median (IQR)         | 14 (12)             | 12 (11)                 | 0.002   |
| IMV dependence < 14 days, n (%)              | 314 (47.87%)        | 530 (55.79%)            | 0.002   |
| IMV dependence ≥ 14 days, n (%)              | 342 (32.13%)        | 420 (44.21%)            |         |
| COVID-19 severity at nadir                   |                     |                         |         |
| Mild/moderate, n (%)                          | 923 (42.57%)        | 5767 (67.19%)           | < 0.001 |
| Severe/critical, n (%)                        | 1245 (57.43%)       | 2816 (32.81%)           |         |
| Admitted to ICU, n (%)                        | 739 (33.73%)        | 1001 (11.52%)           | < 0.001 |
| Length of ICU stay in days, median (IQR)      | 15 (11)             | 14 (12)                 | 0.596   |
| ICU stay ≤ 7 days, n (%)                      | 119 (16.10%)        | 153 (15.28%)            | 0.642   |
| ICU stay > 7 days, n (%)                      | 620 (83.90%)        | 848 (84.72%)            |         |
| Length of hospital stay* in days, median (IQR)| 14 (10)             | 13 (9)                  | < 0.001 |
| Hospital stay ≤ 14 days, n (%)                | 1209 (55.18%)       | 5368 (61.77%)           | < 0.001 |
| Hospital stay > 14 days, n (%)                | 982 (44.82%)        | 3322 (38.23%)           |         |
| Neurologic outcome on discharge**             |                     |                         |         |
| Full/partial neurologic recovery, n (%)       | 368 (76.67%)        | 1271 (89.19%)           | < 0.001 |
| No recovery, n (%)                            | 112 (23.33%)        | 154 (10.81%)            |         |

### Table 3. Association of history of diabetes to the different outcomes of interest. *Individual univariate multiple logistic regression analysis with independent variable diabetes adjusted for age group, sex, smoking history, hypertension, chronic cardiac disease, chronic kidney disease, chronic respiratory disease, chronic neurologic disease, chronic liver disease, and HIV/AIDS.

| Outcomes*                                      | Adj. OR* | 95% CI       | p-value |
|------------------------------------------------|----------|--------------|---------|
| Severe/critical COVID-19 at nadir              | 1.85     | 1.65, 2.07   | < 0.001 |
| Neurological presentation/complication         | 1.17     | 1.03, 1.31   | 0.013   |
| Full/partial neurological improvement          | 1.45     | 0.88, 2.38   | 0.145   |
| In-hospital mortality                          | 1.46     | 1.28, 1.68   | < 0.001 |
| Respiratory failure                            | 1.67     | 1.46, 1.9    | < 0.001 |
| IMV dependence ≥ 14 days                       | 1.33     | 1.08, 1.64   | 0.008   |
| ICU admission                                  | 1.80     | 1.59, 2.05   | < 0.001 |
| ICU stay > 7 days                              | 0.92     | 0.71, 1.21   | 0.555   |
| Hospital stay > 14 days                        | 1.13     | 1.01, 1.26   | 0.027   |

### Table 4. Association of history of diabetes to the different outcomes of interest (time-to-event analysis). *Individual univariate multiple Cox proportional hazards regression analysis with independent variable diabetes adjusted for age group, sex, smoking history, hypertension, chronic cardiac disease, chronic kidney disease, chronic respiratory disease, chronic neurologic disease, chronic liver disease, and HIV/AIDS.

| Outcomes*                                      | Adj. HR*  | 95% CI       | p-value |
|------------------------------------------------|-----------|--------------|---------|
| In-hospital mortality                          | 1.19      | 1.06, 1.33   | 0.002   |
| Respiratory failure                            | 1.51      | 1.35, 1.69   | < 0.001 |
| ICU admission                                  | 1.57      | 1.41, 1.74   | < 0.001 |
(median of 15 days) and non-DM groups (median of 14 days; \( p = 0.596 \)). The adjusted OR for longer LICUS (i.e., more than 7 days) was not significant at 0.92 (95% CI 0.70–1.21; \( p = 0.553 \)).

**Figure 1.** Comparison of Kaplan–Meier curves of in-hospital mortality between COVID-19 patients with diabetes versus non-diabetics, adjusted for the different confounding variables of interest.

**Figure 2.** Comparison of Kaplan–Meier curves of respiratory failure between COVID-19 patients with diabetes versus non-diabetics, adjusted for the different confounding variables of interest.

**Figure 3.** Comparison of Kaplan–Meier curves of being admitted to ICU between COVID-19 patients with diabetes versus non-diabetics, adjusted for the different confounding variables of interest.
Length of hospital stay (LHS). Among the full cohort, the overall median LHS was 13 days (IQR 10–19). There was a significant difference in the median LHS between patients in the DM (median of 14 days) and non-DM groups (median of 13 days; *p* < 0.001). The adjusted OR for longer LHS (i.e., more than 14 days) was statistically significant at 1.13 (95% CI 1.01–1.26; *p* = 0.027).

Discussion

This is the largest cohort study in the Philippines involving 10,881 hospitalized patients with COVID-19 infection and 2191 of this cohort had a history of DM with substantial information on their clinical characteristics. Furthermore, we investigated the effects of the presence of DM on clinically relevant outcomes in these patients.

Patients with DM comprised 20.1% of the entire cohort. This was consistent with studies done in China where 16.2% of patients admitted for COVID-19 also had DM. Within the DM cohort, a considerable number experienced respiratory failure (29.94%), were admitted to the ICU (33.7%), or died (26.4%). The presence of DM as a comorbidity in COVID-19 patients significantly increased the risk of poor outcomes such as mortality, respiratory failure, longer duration of ventilator dependence, ICU admission, COVID-19 severity, and increased length of hospital stay compared to those patients without the disease. On the other hand, the presence of DM was not significantly associated with the length of ICU stay.

Our data showed that with adjustments for age, sex, comorbidities and taking into account the disease severity, the presence of DM increased the odds of dying by 46%. Our gross mortality rates were 26% and 13% for DM and non-DM patients, respectively, both of which were comparable to the data from a multicenter, retrospective study conducted in the United States that looked into the glycemic characteristics and clinical outcomes, where the mortality rate was 28.8% in 184 DM and/or uncontrolled hyperglycemia patients, compared with only 6.2% of 386 patients without DM. The possible reason for the higher mortality in our cohort could be due to poor glycemic control, poor adherence to medications, and less access to diabetes care. A retrospective analysis of 29 patients diagnosed with type 2 DM and laboratory confirmed COVID-19 revealed that two thirds of admitted patients have uncontrolled blood glucose levels, a small number of these presented with either diabetic ketoacidosis or hyperglycemic hyperosmolar state. In a multicenter study in the United States, persistent hyperglycemia of more than 180 mg/dL was associated with a four-fold increase in risk for mortality in patients with COVID-19, rising up to seven-fold among those with pre-existing DM. This was further supported by a meta-analysis done in Italy that compared ICU admissions and mortality among diabetic COVID-19 patients which demonstrated that diabetic patients were at a higher mortality risk (OR 3.21, 95% CI 1.82–5.64, *p* < 0.0001). The presence of DM has always been associated with a poorer prognosis in any infectious disease, but data on its effect in COVID-19 patients remains to be limited. Current data seems to indicate that diabetic patients, as would be expected, have a higher risk of developing more severe complications and higher frequency of ICU admissions. Multiple mechanisms have been postulated to explain the relationship between hyperglycemia and immune dysfunction. These include impairment of white blood cell chemotaxis, phagocytosis, complement function and cytokine dysregulation. Furthermore, immunohistochemical studies of cadaveric pancreatic islet cells revealed similar ACE2 immunostaining pattern to those found in lung alveolar epithelium and myocardium suggesting that ACE2 expression in the pancreas caused by SARS-COV2 invasion and injury leads to pancreatitis resulting in hyperglycemia and mortality. Emerging data on the association between COVID-19 infection and DM have demonstrated that patients diagnosed to have DM have the same probability as the general population in terms of getting infected with COVID-19. However, patients with DM have higher risks of serious complications brought about by COVID-19, and the risks are similar for both type 1 and type 2 DM mellitus. Historical data from the SARS-CoV pandemic from 2002 to 2003, influenza A (H1N1) pandemic in 2009 and Middle East respiratory syndrome coronavirus pandemic in 2012 have all shown poor outcomes among patients with hyperglycemia and poor glycemic control.

In our cohort, we also provided evidence that the presence of DM in COVID-19 infection significantly increased the odds of developing respiratory failure by as much as 67%. DM patients also have 33% increased odds of being dependent on ventilator for more than 14 days than non-DM patients. Our study was also able to shed light on relevant evidence relating DM and severity of infection. Patients with DM have 85% increased odds of having severe/critical COVID-19 at nadir than non-diabetics. Further association studies have shown that there was a 2.26 times increase in the risk of severe infections among COVID-19 with DM resulting in worse overall outcomes. This is supported by a meta-analysis of 1936 COVID-19 patients across the world, which showed a significant correlation between COVID-19 severity and the presence of DM (OR 2.67, 95% CI 1.91–3.74, *p* < 0.01). The number of comorbidities was also identified as a significant risk factor for intensive care unit (ICU) admission and a significant predictor of mortality. Retrospective studies have illustrated the hazard ratios of ICU admission, requirement for invasive mechanical ventilation, and death among those with DM (HR 1.59, 95% CI 1.03–2.45). The HR was 1.79 (95% CI 1.16–2.77) among patients with at least one comorbidity and 2.59 (95% CI 1.61–4.17) among patients with two or more comorbidities. Mortality data from the Chinese Center for Disease Control showed an overall case-fatality rate of 2.3% (1023 deaths in 44,672 cases) in the general population with an increase to 7.3% among those diagnosed with DM. Diabetes, hyperlipidemia, nonalcoholic fatty liver, and atherosclerotic cardiovascular disease often occur together in a single patient and these comorbidities are deeply interrelated. Hence, the new concept of Glucolipid Metabolic Disorders (GLMD) was proposed. Among severe COVID-19 patients, over activation of T cells leads to severe immune-mediated injury resulting in higher concentrations of pro-inflammatory cytokines ending in a cytokine storm that is associated with disease severity. It has been hypothesized that this chronic inflammatory milieu in GLMD patients becomes more activated following COVID-19 infection. There was a significantly increased odds (i.e., 80% increased odds of being admitted to ICU than non-DM) in COVID-19 patients with DM compared to those without DM. This was consistent with the study done in...
Italy where DM patients were at a significantly increased risk of ICU admission (OR: 2.79, 95% CI 1.85–4.22, p < 0.0001)39. Lastly, our results have shown that patients with DM have 13% increased odds of being admitted for > 14 days (median of 14 days). Among 493 discharged survivors in the United States, the median length of stay was longer in 184 patients with DM compared with 386 patients without DM or hyperglycemia (5.7 vs 4.3 days, p < 0.001)40.

Our study has several limitations. Our data only reflected exposures and outcomes of hospitalized COVID-19 patients thus, the information from patients who were not admitted was not captured. Moreover, because only admitted patients were involved in this study, mortality and respiratory failure are expected to be overestimated since substantially more severe and critical COVID-19 cases are admitted in a hospital setting. We were also not able to account for the higher utilization of steroids, tocilizumab, and anti-viral medications in our DM cohort. The duration, type of DM, presence of microvascular and macrovascular complications, and history of diabetic emergencies were not determined, nor was the level of glycemic control (fasting blood glucose levels and baseline hemoglobin A1c levels), and the treatment regimens of the patients. Future studies focusing on the aforementioned parameters are needed to further establish the role and interaction between the presence of DM, DM complications and the level of glycemic control on its effect on clinical outcomes among COVID-19 patients.

Conclusion
The presence of diabetes mellitus among COVID-19 patients significantly increases the risk of mortality, respiratory failure, duration of ventilator dependence, severe/critical COVID-19, ICU admission, and length of hospital stay.

References
1. Coronavirus disease (COVID-19). Accessed July 19, 2021. https://www.who.int/emergencies/diseases/novel-coronavirus-2019.
2. Department of Health website. Accessed at: https://doh.gov.ph/2019-nCoV. Accessed July 19, 2021.
3. Yang, J., Zheng, Y., Gou, X., Pu, K. & Chen, Z. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: A systematic review and meta-analysis. Int. J. Infect. Dis. 94, 91–95 (2020).
4. Carey, I. M. et al. Risk of infection in type 1 and type 2 diabetes compared with the general population: a matched cohort study. Diabetes Care 41, 513–521 (2018).
5. McDonald, H. I., Nitsch, D., Millett, E. R., Sinclair, A. & Thomas, S. L. New estimates of the burden of acute community-acquired infections among older people with diabetes mellitus: A retrospective cohort study using linked electronic health records. Diabet Med. 31, 606–614 (2014).
6. Muniyappa, R. & Gubbi, S. COVID-19 pandemic, coronaviruses, and diabetes mellitus. Am. J. Physiol. – Endocrinol. Metab. 318, E736–E741 (2020).
7. Kubo, K., Imai, Y., Rao, S., Jiang, C. & Penninger, J. M. Lessons from SARS: control of acute lung failure by the SARS receptor ACE2. J. Mol. Med. 84, 814–820 (2006).
8. Wang, D. et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA 323, 1061–1069 (2020).
9. Liu, F., Long, X., Zhang, B., Zhang, W. & Chen, X. ACE2 expression in pancreas may cause pancreatic damage. Clin. Gastroenterol. Hepatol. 18, 2128–2130 (2020).
10. Ji, H. L., Zhao, R., Matalon, S. & Matthey, M. A. Elevated plasminogen as a common risk factor for COVID-19 susceptibility. Physiol. Rev. 100, 1065–1075 (2020).
11. Xue, J. et al. Risk factors for prolonged viral clearance in adult patients with COVID-19 in Beijing, China: A prospective observational study. Int. Immunopharmacol. 89 (Pt A), 107031 (2020).
12. Bloomgarden, Z. T. Diabetes and COVID-19. J. Diabetes 12, 347–348 (2020).
13. Hussain, A., Bhowmik, B. & de Vale Moreira, N. C. COVID-19 and diabetes: Knowledge in progress. Diabetes Res. Clin. Pract. 162, 1–9 (2020).
14. Zhou, J. & Tan, J. Diabetes patients with COVID-19 need better blood glucose management in Wuhan, China. Metabolism 107, 1–2 (2020).
15. Ma, W. X. Ran XW [The Management of blood glucose should be emphasized in the treatment of COVID-19]. Sichuan Da Xue Xue Bao Yi Xue Ban 51, 146–150 (2020).
16. Bode, B. et al. Glycemic characteristics and clinical outcomes of COVID-19 patients hospitalized in the United States. J. Diabetes Sci. Technol. 14, 813–821 (2020).
17. Fadini, G. P., Morieri, M. L., Longato, E. & Avogaro, A. Prevalence and impact of diabetes among people infected with SARS-CoV-2. Diabetes Metab. Investigat. 43, 867–869 (2020).
18. Chen, Y., Gong, X., Wang, L. & Guo, J. Effects of hypertension, diabetes and coronary heart disease on COVID-19 diseases severity: A systematic review and meta-analysis. medRxiv [Preprint]. March 30, 2020 (cited July 19, 2021). https://doi.org/10.1101/2020.03.25.20043133.
19. Ruan, Q., Yang, K., Wang, W., Jiang, L. & Song, J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 46, 846–848 (2020).
20. Roncon, L., Zuin, M., Rigatelli, G. & Zuliani, G. Diabetic patients with COVID-19 infection are at higher risk of ICU admission and poor short-term outcome. J. Clin. Virol. 127, 104354 (2020).
21. Gupta, R., Ghosh, A., Singh, A. K. & Misra, A. Clinical considerations for patients with diabetes in times of COVID-19 epidemic. Diabetes Metab. Syndr. 14, 211–212 (2020).
22. Fang, L., Karakiaaslak, G. & Roth, M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir. Med. 8, e21 (2020).
23. Espiritu, A. I., Sy, M. C., Anlacan, V. M. & Jamora, R. D. The Philippine COVID-19 outcomes: A retrospective study of neurological manifestations and associated symptoms (The Philippine CORONA Study): a protocol study. BMJ Open 10, e040944 (2020).
24. Espiritu, A. I., Sy, M. C., Anlacan, V. M., Jamora, R. D., The Philippine CORONA Study Group Investigators. COVID-19 outcomes of 10,881 patients: Retrospective study of neurological symptoms and associated manifestations (Philippine CORONA Study). J. Neural Trans. (Vienna) 128, 1687–1703 (2021).
25. Yang, J. K., Lin, S. S., Li, X. J. & Guo, L. M. Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes. Acta Diabetes. 47, 193–199 (2010).
26. Guan, W. J. et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: A nationwide analysis. *Eur. Respir. J.*, 55, 640 (2020).

27. Wu, Z. & McGoogan, J. M. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. *JAMA* 323, 1239–1242 (2020).

28. Guo, J. Research progress on prevention and treatment of glucolipid metabolic disease with integrated traditional Chinese and Western medicine. *Chin. J. Integr. Med.* 23, 403–409 (2017).

Author contributions
A.I.E.: Conceptualization, data curation, formal analysis, interpretation of data, writing-review, and editing, study supervision, and final approval of the version to be published. H.H.C.: Data curation, formal analysis, interpretation of data, writing-original draft, writing-review, and editing. M.C.S.: Conceptualization, data curation, formal analysis, interpretation of data, writing-original draft, writing-review, and editing. V.M.A.: Conceptualization, data curation, formal analysis, interpretation of data, writing-original draft, writing-review, and editing, study supervision, and final approval of the version to be published. P.C.S.G.: Data collection and curation and final approval of the version to be published. R.D.J.: Conceptualization, data curation, formal analysis, interpretation of data, writing-original draft, writing-review, and editing, study supervision, and final approval of the version to be published.

Funding
The study was supported by the Philippine Neurological Association (Grant number: Not applicable) and the Expanded Hospital Research Office, University of the Philippines Manila (Grant number: Not applicable).

Competing interests
The authors declare no competing interests.

Additional information
Supplementary Information The online version contains supplementary material available at https://doi.org/10.1038/s41598-021-03898-1.

Correspondence and requests for materials should be addressed to A.I.E. or R.D.G.J.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021

The Philippine CORONA Study Group
Corina Maria Socorro A. Macalintal, Joanne B. Robles, Paulo L. Cataniag, Manolo Kristoffer C. Flores, Noreen Jhoanna C. Tanguanoco-Trinidad, Dan Neftalie A. Juangco, Giuliani Renz G. Paas, Audrey Marie U. Chua, Valmarie S. Estrada, Philip Rico P. Mejia, Therese Franz B. Reyes, Maria Teresa A. Cañete, Ferdinand Renfred A. Zapata, Franko Eugenio B. Castillo, Romulo U. Esagunde, Jean B. Gantioque, Maritoni C. Abbariao, Geramie M. Abebuque, Evram V. Corral, Marian Irene C. Escasura, Marissa T. Ong, Krizelle Fowler, Arnold Angelo M. Pineda, Khasmeen D. Aradani, Josee-an S. Catindig, Mark Timothy T. Cinco, Mark Erving H. Ramos, Romulus Emmanuel H. Cruz, Marita B. Dantes, Norberto A. Francisco, Rosaliza A. Teleg, Krisverlyn B. Bellosillo, Jean Paolo M. Delfino, Cid Czarina E. Diesta, Rosalina B. Espiritu-Picar, Julie Anne V. Gamboa, Cara Camille M. Matute, Franzelle P. Padilla, John Joshua Q. Punsalan, Ma. Epifania V. Collantes, Charmaine B. Que, Hanifa A. Sampao, Maxine Camela S. Sta. Maria, Maritza M. Fuentes, Jennifer Justice F. Manzano, Rizza J. Umali, Marc Conrad C. Molina, Hazel Claire Minerva-Ang, Arturo F. Surdilla, Loreto P. Talabucon Jr.
Natasha F. Wabe24, Maria Victoria G. Manuel25, Al Inde John A. Pajantoy25, Josephine Cecilia V. Roque25, Paul Emmanuel L. Yambao25, Christian Paul B. Banday26, Christopher C. Cipriano26, Nehar A. Pangandaman26, Avery Gail C. Wasil26, Elrey P. Inocian27, Jarungchai Anton S. Vatanagu27, Almira Doreen Abigail O. Apor28, Carissa Paz C. Dioquino28, Prinz Andrew M. dela Cruz29, Maricar P. Yumul29, Ma. Alma E. Carandang-Concepcion30, Ma. Caridad V. Desquitado31, Carl Kevin L. Julao31, Dante P. Bornales32, Generaldo D. Maylem33, Mark Joseph F. Cuntapay33, Annabelle Y. Lao-Reyes34, Aileen Mae B. Lee34, Nadia O. Manlegro34, Dave Mar L. Pelere34, Lina C. Laxamana35, Diana-Lynn S. Que35, Jeryl Ritzi T. Yu35, Ma. Socorro C. Martinez36, Alexandra E. Matic36, John Angelo Luis S. Perez36, Glenn Anthony A. Constantino37, Aldanica R. Olano37, Liz Edenberg P. Quiles37, Artemio A. Roxas Jr.37, Jo Ann R. Soliven37, Michael Dorothy Frances Montojo-Tamayo37, Ma. Lourdes C. Joson38, Jojo R. Evangelista38, Ma. Clarissa B. Nuñez39, Marietta C. Olaivar39, Dominique O. Perez39, Mark Deneb O. Armeña40, Robert A. Barja40, Joshua Emmanuel E. Abejero41, Maritzie R. Eribal41, Ryndell G. Alava42, Muktader A. Kalbi43, Nasheera W. Radja43 & Mohammad Elshad S. Sali43

6Asian Hospital and Medical Center, Muntinlupa City, Philippines. 7Baguio General Hospital and Medical Center, Baguio City, Philippines. 8Cagayan Valley Medical Center, Tuguegarao City, Philippines. 9Capitol Medical Center, Quezon City, Philippines. 10Cardinal Santos Medical Center, San Juan City, Philippines. 11Chong Hua Hospital, Cebu City, Philippines. 12De La Salle University Medical and Health Sciences Institute, Dasmariñas City, Philippines. 13Dr. Jose N. Rodriguez Memorial and Sanitarium Hospital, Caloocan City, Philippines. 14Dr. Pablo O. Torre Memorial Hospital, Bacolod City, Philippines. 15East Avenue Medical Center, Quezon City, Philippines. 16Institute of Dementia Care Asia, Quezon City, Philippines. 17Jose B. Lingad Memorial Regional Hospital, City of San Fernando, San Fernando, Philippines. 18Jose R. Reyes Memorial Medical Center, Manila, Philippines. 19Lung Center of the Philippines, Quezon City, Philippines. 20Makati Medical Center, Makati City, Philippines. 21Manila Doctors Hospital, Manila, Philippines. 22Medical Center Manila, Manila, Philippines. 23New Era General Hospital, Quezon City, Philippines. 24Northern Mindanao Medical Center, Cagayan de Oro City, Philippines. 25Quirino Memorial Medical Center, Quezon City, Philippines. 26Ospital Ng Makati, Makati City, Philippines. 27Perpetual Succour Hospital, Cebu City, Philippines. 28Philippine General Hospital, Manila, Philippines. 29Philippine Heart Center, Quezon City, Philippines. 30Research Institute for Tropical Medicine, Muntinlupa City, Philippines. 31San Juan De Dios Educational Foundation Inc.– Hospital, Pasay City, Philippines. 32San Lazaro Hospital, Manila, Philippines. 33Southern Isabela Medical Center, Santiago, Philippines. 34Southern Philippines Medical Center, Davao City, Philippines. 35St. Luke’s Medical Center – Global City, Taguig City, Philippines. 36St. Luke’s Medical Center, Quezon City, Philippines. 37The Medical City, Pasig City, Philippines. 38University of Santo Tomas Hospital, Manila, Philippines. 39University of the East Ramon Magsaysay Memorial Medical Center Inc., Quezon City, Philippines. 40Veterans Memorial Medical Center, Cebu City, Philippines. 41Vicente Sotto Memorial Medical Center, Cebu City, Philippines. 42Western Visayas Medical Center, Iloilo City, Philippines. 43Zamboanga City Medical Center, Zamboanga City, Philippines.